title: Somatostatin-receptor scintigraphy in primary breast cancer.
abstract: Somatostatin-receptor (SS-R) scintigraphy successfully shows primary cancers and distant metastases in most patients with carcinoids, islet cells tumours, and paragangliomas. Previous in-vitro studies indicated that somatostatin receptors are present in human breast cancers. We report positive scintigraphy with [111In-DTPA-D-Phe1]-octreotide in 39 of 52 primary breast cancers (75%). Parallel in-vitro autoradiography with [125I-Tyr3]-octreotide of 30 of these showed a corresponding somatostatin-receptor status in 28. Significantly more invasive ductal cancers could be shown than invasive lobular carcinomas (85% vs 56%; p < 0.05). Also the number of T2 cancers which were shown was higher than T1 (86% vs 61%; p < 0.05). Imaging of the axillae showed non-palpable cancer-containing lymph nodes in 4 of 13 patients with subsequently histologically-proven metastases. In the follow-up after a mean of 2.5 yr, SS-R scintigraphy in 28 of the 37 patients with an originally SS-R-positive cancer, was positive in the 2 patients with clinically-recognised metastases, as well as in 6 of the remaining 26 patients who were symptom-free. Raised carcinoembryonic antigen (CEA) and CA 15-3 values were observed in only 2 and 1, respectively, of these patients. Most primary breast cancers can be shown by SS-R scintigraphy, especially invasive ductal cancers. This technique may be of value in selecting patients for clinical trials with somatostatin analogues or other medical treatments. Furthermore, SS-R scintigraphy is more sensitive than measurements of the usual serum cancer markers for detecting recurrences of SS-R-positive breast cancer.
authors.affiliation: Department of Surgery, Erasmus University, Rotterdam, Netherlands.
authors.forename: C H
authors.initials: CH
authors.lastname: van Eijck
authors.forename: E P
authors.initials: EP
authors.lastname: Krenning
authors.forename: A
authors.initials: A
authors.lastname: Bootsma
authors.forename: H Y
authors.initials: HY
authors.lastname: Oei
authors.forename: R
authors.initials: R
authors.lastname: van Pel
authors.forename: J
authors.initials: J
authors.lastname: Lindemans
authors.forename: J
authors.initials: J
authors.lastname: Jeekel
authors.forename: J C
authors.initials: JC
authors.lastname: Reubi
authors.forename: S W
authors.initials: SW
authors.lastname: Lamberts
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000097:blood; D001345:Autoradiography; D001940:Breast / Q000737:chemistry / Q000000981:diagnostic imaging / Q000473:pathology; D001943:Breast Neoplasms / Q000737:chemistry / Q000175:diagnosis / Q000000981:diagnostic imaging* / Q000473:pathology; D002272:Carcinoembryonic Antigen / Q000097:blood; D005260:Female; D006801:Humans; D008198:Lymph Nodes / Q000000981:diagnostic imaging; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000000981:diagnostic imaging*; D015282:Octreotide; D011877:Radionuclide Imaging; D017481:Receptors, Somatostatin / Q000032:analysis*
chemical_list: D015295:Antigens, Tumor-Associated, Carbohydrate; D002272:Carcinoembryonic Antigen; D017481:Receptors, Somatostatin; D015282:Octreotide